BioCentury
ARTICLE | Company News

Merck, GlaxoSmithKline deal

November 23, 2015 8:00 AM UTC

The companies partnered to conduct a U.S. Phase I trial to evaluate Merck’s Keytruda pembrolizumab with GlaxoSmithKline’s GSK3174998 to treat patients with locally advanced, recurrent or metastatic solid tumors that have progressed after standard treatment. GSK is sponsoring the trial. ...